Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 20/20 | 0.59 |
| ▸ | KIT | P10721 | 2/20 | 0.45 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13765699 | 0.94 | PDGFRB (0.61) | PDGFRBKITFLT3FGFR1PDGFRA | |
| SCHEMBL13360876 | 0.89 | PDGFRB (0.66) | PDGFRBKITFLT3CSF1R | |
| SCHEMBL13330467 | 0.78 | PDGFRB (0.95) | PDGFRBKITFLT3CSF1RFGFR1 | |
| SCHEMBL13105997 | 0.75 | PDGFRB (0.64) | PDGFRBKITFLT3CSF1RFGFR1 | |
| SCHEMBL13360952 | 0.73 | PDGFRB (0.52) | PDGFRBKITFLT3FGFR1PDGFRA | |
| SCHEMBL13330456 | 0.70 | PDGFRB (1.00) | PDGFRBKITFLT3FGFR1PDGFRA | |
| SCHEMBL13330468 | 0.70 | PDGFRB (0.88) | PDGFRBKITFLT3CSF1RFGFR1 | |
| SCHEMBL906269 | 0.67 | PDGFRB (1.00) | PDGFRBKITFLT3CSF1R | |
| SCHEMBL13773428 | 0.66 | PDGFRB (0.58) | PDGFRBKITFLT3CSF1RFGFR1 | |
| SCHEMBL13932716 | 0.66 | SRC (0.39) | FGFR1FGFR2FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324205-B2 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100113468-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-7560461-B2 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113468-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | PDGFRB 10/4885KIT 495/4885FLT3 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.